

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

Phospho-Met (Tyr1234/1235) Antibody

RRID:AB_331713

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3126, RRID:AB_331713

Antibody Information

URL: http://antibodyregistry.org/AB_331713

Proper Citation: Cell Signaling Technology Cat# 3126, RRID:AB_331713

Target Antigen: Phospho-Met (Tyr1234/1235)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10078677, AB_10078678, AB_331713, AB_331714.

Antibody Name: Phospho-Met (Tyr1234/1235) Antibody

Description: This polyclonal targets Phospho-Met (Tyr1234/1235)

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_331713

Vendor: Cell Signaling Technology

Catalog Number: 3126

Record Creation Time: 20231110T081401+0000

Record Last Update: 20260829T212343+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Met (Tyr1234/1235) Antibody.

No alerts have been found for Phospho-Met (Tyr1234/1235) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Poliakov?? Turan M, et al. (2024) E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. Cancer research communications, 4(7), 1863.

Mertz JL, et al. (2021) Proteomic and phosphoproteomic analyses identify liver-related signaling in retinal pigment epithelial cells during EMT. Cell reports, 37(3), 109866.

Fu H, et al. (2021) The hepatocyte growth factor/c-met pathway is a key determinant of the fibrotic kidney local microenvironment. iScience, 24(10), 103112.

Day EK, et al. (2020) Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling. Cell reports, 30(10), 3383.

Greenfield E, et al. (2014) Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors. eLife, 3.